IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences Inc. is based in South San Francisco, United States.
Revenue (Most Recent Fiscal Year) | $23.39M |
Net Income (Most Recent Fiscal Year) | $-112.96M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 119.95 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.90 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -483.05% |
Net Margin (Trailing 12 Months) | -483.05% |
Return on Equity (Trailing 12 Months) | -23.00% |
Return on Assets (Trailing 12 Months) | -21.78% |
Current Ratio (Most Recent Fiscal Quarter) | 19.65 |
Quick Ratio (Most Recent Fiscal Quarter) | 19.65 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $9.64 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.52 |
Earnings per Share (Most Recent Fiscal Year) | $-1.96 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.97 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 74.56M |
Free Float | 70.76M |
Market Capitalization | $2.80B |
Average Volume (Last 20 Days) | 0.52M |
Beta (Past 60 Months) | 0.80 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 5.10% |
Percentage Held By Institutions (Latest 13F Reports) | 98.29% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |